Ambu A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0060946788
DKK
87.90
-108.02 (-55.14%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.01 M

Shareholding (Jun 2023)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 20,654 Million ()

stock-summary
P/E

69.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.87%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

9.01%

stock-summary
Price to Book

3.42

Revenue and Profits:
Net Sales:
1,507 Million
(Quarterly Results - Jun 2025)
Net Profit:
123 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-60.46%
0%
-60.46%
6 Months
-62.09%
0%
-62.09%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Ambu A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
9.76%
EBIT Growth (5y)
7.42%
EBIT to Interest (avg)
9.56
Debt to EBITDA (avg)
1.09
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.83
Tax Ratio
15.53%
Dividend Payout Ratio
17.94%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
6.79%
ROE (avg)
5.61%

Valuation key factors

Factor
Value
P/E Ratio
69
Industry P/E
Price to Book Value
4.19
EV to EBIT
53.53
EV to EBITDA
20.88
EV to Capital Employed
4.61
EV to Sales
4.04
PEG Ratio
NA
Dividend Yield
1.44%
ROCE (Latest)
8.61%
ROE (Latest)
6.08%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.97% vs 15.73% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.21% vs 162.75% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,507.00",
          "val2": "1,383.00",
          "chgp": "8.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "263.00",
          "val2": "267.00",
          "chgp": "-1.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.00",
          "val2": "7.00",
          "chgp": "85.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "123.00",
          "val2": "134.00",
          "chgp": "-8.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "112.80%",
          "val2": "128.70%",
          "chgp": "-1.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 12.90% vs 7.45% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 39.88% vs 80.65% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,391.00",
          "val2": "4,775.00",
          "chgp": "12.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,006.00",
          "val2": "632.00",
          "chgp": "59.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "27.00",
          "val2": "61.00",
          "chgp": "-55.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-331.00",
          "val2": "-7.00",
          "chgp": "-4,628.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "235.00",
          "val2": "168.00",
          "chgp": "39.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "119.10%",
          "val2": "63.20%",
          "chgp": "5.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
1,507.00
1,383.00
8.97%
Operating Profit (PBDIT) excl Other Income
263.00
267.00
-1.50%
Interest
13.00
7.00
85.71%
Exceptional Items
0.00
0.00
Consolidate Net Profit
123.00
134.00
-8.21%
Operating Profit Margin (Excl OI)
112.80%
128.70%
-1.59%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 8.97% vs 15.73% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -8.21% vs 162.75% in Jun 2024

Annual Results Snapshot (Consolidated) - Sep'24stock-summary

Sep'24
Sep'23
Change(%)
Net Sales
5,391.00
4,775.00
12.90%
Operating Profit (PBDIT) excl Other Income
1,006.00
632.00
59.18%
Interest
27.00
61.00
-55.74%
Exceptional Items
-331.00
-7.00
-4,628.57%
Consolidate Net Profit
235.00
168.00
39.88%
Operating Profit Margin (Excl OI)
119.10%
63.20%
5.59%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is 12.90% vs 7.45% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 39.88% vs 80.65% in Sep 2023

stock-summaryCompany CV
About Ambu A/S stock-summary
stock-summary
Ambu A/S
Pharmaceuticals & Biotechnology
Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products from resuscitators, face masks and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
Company Coordinates stock-summary
Company Details
Baltorpbakken 13 , BALLERUP None : 2750
stock-summary
Tel: 45 72 25200045 26 208047
stock-summary
Registrar Details